AstraZeneca
AstraZeneca allowed to recruit for drug trial again
November 22, 2016Manufacturing and Production, Research and Development AstraZeneca, FDA, clinical trial
AstraZeneca’s clinical trial for head and neck cancer had previously been put on partial hold by the FDA due to …
AstraZeneca’s post-heart attack drug gets NICE recommendation
November 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
AstraZeneca’s head and neck cancer treatment clinical trials put on hold
October 31, 2016Sales and Marketing AstraZeneca, clinical hold, clinical trials, immunotherapy, phase III
AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …
AZ reveals compelling PhIII data for ovarian cancer treatment
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …
EMA opens clinical trial data to public
October 25, 2016Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials
The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
AstraZeneca forced to abandon Phase II trial
October 12, 2016Research and Development AstraZeneca, Synairgen, asthma, cold, common cold
Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
NICE recommends Forxiga in Triple Therapy for Diabetes
October 7, 2016Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes
The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …
AstraZeneca sells off third drug in five days
October 7, 2016Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua
AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …
AZ “disappointment” at heart drug failure
October 5, 2016Research and Development AZ, AstraZeneca, trial failure
AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
AstraZeneca’s wins major drug approval by NICE
October 4, 2016Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso
AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Zuckerberg appoints AstraZeneca’s Cornelia Bargmann
September 28, 2016Research and Development AstraZeneca, Facebook, Mark Zuckerberg, Priscilla Chan
Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …
AZ withdraws European filing for ovarian cancer therapy
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer
AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …
AstraZeneca and Microsoft to develop ‘drag and drop’ cancer simulation
September 21, 2016Medical Communications, Research and Development AstraZeneca, Digital Pharma Guide, Microsoft
AstraZeneca has entered into a partnership with tech giant Microsoft to develop a new computerised modelling system which promises to …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
